Treating to Target-A Realistic Goal in Psoriasis? Semin Cutan Med Surg 2018 Feb;37(2S):S44-S47
Date
04/04/2018Pubmed ID
29614137DOI
10.12788/j.sder.2018.010Abstract
For many patients, the new biologic therapies for psoriasis can improve Psoriasis Area and Severity Index (PASI) scores in a relatively short time. But when results are less than optimal, patients often become frustrated. By providing effective medical treatment using a treat-to-target strategy, clinicians can relieve symptoms and halt disease progression. Although body surface area (BSA) and PASI scores are appropriate for analyzing results of clinical trials, clinicians need to use more patient-centered assessments of patients' progress such as the Dermatology Life Quality Index (DLQI) and Psoriasis Symptom Inventory (PSI), as well as other validated patientreported outcomes, which can enable them to set realistic and achievable goals for individual patients. Semin Cutan Med Surg 37(supp2):S44-S47.
Author List
Gordon KB, Armstrong AW, Menter MA, Wu JJAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultBiological Products
Body Surface Area
Dermatologic Agents
Humans
Male
Patient Preference
Patient Reported Outcome Measures
Psoriasis
Quality of Life
Severity of Illness Index
Treatment Outcome
